Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member printed attachment file name file name title title question first answered question first ministerially corrected answering member label previous answer version answering member printed attachment file name file name title title answering member label
tabling member	label

Search

1483317

registered interest
date	27/06/2022
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Cervical Cancer: Screening
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government what estimate they have made of the efficacy of the invitation issued by the NHS Cervical Screening Programme which is addressed to women, people with a cervix and trans men if they have a cervix; and what steps they will take to ensure that the provision of cervical screening services is not degraded by a lack of clarity concerning eligibility for them.
tabling member printed	Baroness Deech
uin	HL1269
answer	answer is ministerial correction date of answer 19/07/2022 answer text <p><del class="ministerial">The Community Pharmacy Contractual Framework 2019-24 sets out how community pharmacy will support the NHS Long Term Plan, integrate with the National Health Service and provide more clinical services, such as advice and treatment for minor illnesses. A range of services have been introduced, including the Community Pharmacist Consultation Service which allows general practices and NHS 111 to refer patients to community pharmacies for minor illnesses.</del></p><p><del class="ministerial">The majority of community pharmacies also offer blood pressure checks and further support for patients who have been prescribed specific new medicines. Negotiations on additional support which could be provided by sector are ongoing. NHS England is piloting services which could be introduced, including the direct referral of people with potential symptoms of cancer, minor illness referrals from urgent and emergency care settings and the supply of contraception.</del></p><p><del class="ministerial">New standards for initial education and training will ensure that all new pharmacists entering the profession will be equipped with the skills and knowledge to undertake greater clinical roles and provision of healthcare services, including enhanced learning to become independent prescribers upon registration.</del></p><p><ins class="ministerial"> <p><ins class="ministerial">We are aware that cancer screening coverage is lower in lesbian, gay, bisexual, and transgender communities. Such inequalities are due partially to individuals being unsure which National Health Service screening programmes they are eligible for or how to access screening if they are not automatically invited. We have therefore worked with Cancer Research UK and Jo’s Cervical Cancer Trust to amend the language used in cervical screening to include ‘women and anyone with a cervix’. The same terminology has also been applied to the NHS cervical screening leaflet.</ins><ins class="ministerial"></ins></p></ins><ins class="ministerial"><p><ins class="ministerial">We have also provided a leaflet for transgender and non-binary individuals, which explains which patient groups the NHS invites for screening and how eligible people can access screening if they are not automatically invited.</ins></p></ins></p> answering member printed Lord Kamall question first answered 19/07/2022 12:57:16 question first ministerially corrected 19/07/2022 16:54:44 answering member 4909 label Biography information for Lord Kamall previous answer version 13888 answering member printed Lord Kamall answering member 4909 label Biography information for Lord Kamall
tabling member	3756 label Biography information for Baroness Deech

1472712

registered interest
date	22/06/2022
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Health Professions: Dermatology
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government what steps they are taking to address shortages in the dermatology workforce in England; and what assessment they have made of the potential role of (1) tele-dermatology for diagnostic support and triage, (2) GPs, (3) nurses, and (4) pharmacists, in increasing capacity for treatment and monitoring of skin disorder.
tabling member printed	Baroness Finlay of Llandaff
uin	HL1184
answer	answer is ministerial correction date of answer 07/07/2022 answer text <p>Following the 2021 Spending Review, we are increasing the number training posts in dermatology in England <del class="ministerial">to</del> <ins class="ministerial">by </ins>15, with doctors in postgraduate training in post from August 2022. The National Health Service is also ensuring that patients can access specialist care through dermatology outpatient services. This focuses on a personalised approach for patients waiting for outpatient appointments, improving waiting times and offering choice for patients at the point of referral. Pharmacies can offer clinical advice and over-the-counter medicines for many skin conditions and where appropriate pharmacists can advise the patient to consult a general practitioner (GP), nurse or other healthcare professional.</p><p> </p><p>Many dermatology departments in England now offer a rapid access Teledermatology Advice and Guidance service for GPs to seek advice from a specialist prior to a referral being made. The use of technology, such as digital images, reduces unnecessary face-to-face appointments and provides flexibility for patients when booking outpatient appointments.</p><p> </p><p>A Teledermatology Roadmap for 2020-21 v1.0 provides recommendations on optimising teledermatology triage and specialist advice, including establishing a working group of multidisciplinary clinical leads and other stakeholders. A copy of the Roadmap is attached. The two-week wait skin cancer pathway: innovative approaches to support early diagnosis of skin cancer as part of the NHS COVID-19 recovery plan also includes a new virtual pathway using teledermatology. A copy of the guidance for the skin cancer pathway is attached.</p> answering member printed Lord Kamall attachment 1 file name NOTP Teledermatology Roadmap 202021 v10 FINAL (1).pdf title A Teledermatology Roadmap for 2020-21 v1.0 2 file name B0829-suspected-skin-cancer-two-week-wait-pathway-optimisation-guidance (1).pdf title The two-week wait skin cancer pathway: innovative question first answered 07/07/2022 16:32:46 question first ministerially corrected 26/07/2022 14:02:01 answering member 4909 label Biography information for Lord Kamall previous answer version 11525 answering member printed Lord Kamall attachment 1 file name NOTP Teledermatology Roadmap 202021 v10 FINAL (1).pdf title A Teledermatology Roadmap for 2020-21 v1.0 2 file name B0829-suspected-skin-cancer-two-week-wait-pathway-optimisation-guidance (1).pdf title The two-week wait skin cancer pathway: innovative answering member 4909 label Biography information for Lord Kamall
tabling member	3609 label Biography information for Baroness Finlay of Llandaff

1400128

registered interest
date	05/01/2022
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Coronavirus: Screening
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government, following the introduction of updated COVID-19 test validation approval processes (CTDA), what guidance is available to testing manufacturers regarding submitting applications (1) for new tests and (2) for an updated approved product; and what is the expected timescale from application to decision for such applications.
tabling member printed	Baroness Finlay of Llandaff
uin	HL5111
answer	answer is ministerial correction date of answer 07/03/2022 answer text <p><del class="ministerial">On 21 February 2022, the Government accepted advice from the Joint Committee on Vaccination and Immunisation (JCVI) on offering a further dose to some individuals. The primary aim is to reduce the risk of severe disease across the population. As protection against severe COVID-19 disease declines slowly, the most vulnerable groups have been prioritised for vaccination.</del></p><p><del class="ministerial">A dose will be offered to those over the age of 75 years old, residents in care homes for older adults and people aged 12 years and over who are immunosuppressed. The JCVI continues to consider the latest available data on the timing and value of further doses.</del></p><p><ins class="ministerial"> <p><ins class="ministerial">The online only guidance COVID-19 test approval: how to apply advises testing manufacturers on the validation process for new devices. The guidance sets out the process from submitting an application; the desktop review; how payment can be made; the outcome reporting on tests which have passed; how to make a complaint; and where an application is unsuccessful, how the manufacturer can request a review of the decision.</ins><ins class="ministerial"></ins></p></ins><ins class="ministerial"><p><ins class="ministerial">For updates to products while an application is being considered, applicants must inform the COVID-19 Test Device Validation Approval processes (CTDA) administration team and provide the updated Instructions for Use. For updates to approved products, manufacturers are encouraged to contact the CTDA administration team. Guidance for such updates is currently being developed.</ins></p><p><ins class="ministerial">The CTDA team aim to have the results of the application review within 20 working days of submission, subject to the application being complete. This process may take longer where there is a high volume of applications and if there are additional queries on the data submitted.</ins></p></ins></p> answering member printed Lord Kamall question first answered 07/03/2022 15:56:05 question first ministerially corrected 10/03/2022 11:19:47 answering member 4909 label Biography information for Lord Kamall previous answer version 55652 answering member printed Lord Kamall answering member 4909 label Biography information for Lord Kamall
tabling member	3609 label Biography information for Baroness Finlay of Llandaff

1366282

registered interest
date	04/11/2021
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Coronavirus: Ventilation
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government what steps they are taking to promote ventilation in buildings to minimise the spread of COVID-19.
tabling member printed	Lord Bourne of Aberystwyth
uin	HL3721
answer	answer is ministerial correction date of answer 10/12/2021 answer text <p>The Government has published <ins class="ministerial">Ventilation of indoor spaces to stop the spread of coronavirus (COVID-19)</ins> <del class="ministerial">Ventilation of indoor spaces on how to improve the spread of coronavirus (COVID-19)</del> in an online only format. This guidance stresses the importance of practical steps such as opening windows and doors; making sure small vents or grilles are open and not blocked; and ensuring that any mechanical ventilation system is working and maintained in line with manufacturers’ instructions. Ventilation systems should bring fresh air in and not recirculate indoor air. In workplaces and non-domestic settings, ventilation should be considered alongside other control measures to reduce the risk of COVID-19.</p> answering member printed Lord Kamall question first answered 10/12/2021 11:26:13 question first ministerially corrected 13/12/2021 19:04:40 answering member 4909 label Biography information for Lord Kamall attachment 1 file name Ventilation of indoor spaces to stop the spread of coronavirus (COVID-19) - GOV.UK.pdf title Ventilation of indoor spaces to stop the spread of previous answer version 38253 answering member printed Lord Kamall answering member 4909 label Biography information for Lord Kamall attachment 1 file name Ventilation of indoor spaces to stop the spread of coronavirus (COVID-19) - GOV.UK.pdf title Ventilation of indoor spaces to stop the spread of
tabling member	4282 label Biography information for Lord Bourne of Aberystwyth

1362396

registered interest
date	21/10/2021
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Oral Tobacco
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government why they maintain a ban on snus products.
tabling member printed	Lord Jones of Cheltenham
uin	HL3286
answer	answer is ministerial correction date of answer 15/11/2021 answer text <p>Consumption of any tobacco product is harmful and it is the Government’s policy to support people to quit all forms of tobacco use. Oral tobacco, or snus, is banned in the United Kingdom under the Tobacco and Related Products Regulations 2016.</p><p>There is limited data on the health risks posed to smokers who switch to snus products. Evidence submitted on snus to the United States Food and Drug Administration states that there are still health risks involved with the use of snus. Although snus products contain significantly lower levels of harmful carcinogens than other smokeless tobacco products, the products contain nitrosamines, including NNN and NNK, which have been demonstrated to cause cancer, including cancers of the mouth. A copy of this evidence, <em>Modified Risk Tobacco Product (MRTP) ApplicationTechnical Project Lead (TPL) Review</em>, is attached.</p><p><em>Health risks of Scandinavian snus consumption (English summary)</em> from Norway shows that tobacco products such as oral tobacco contains carcinogenic substances which are associated with a number of adverse health effects. This is regardless of whether the individual is a smoker or not. A copy of this summary is attached.</p> answering member printed Lord Kamall attachment 1 file name health-risks-of-scandinavian-snus-consumption-english-summary-pdf.pdf title Health risks of Scandinavian snus consumption 2 file name SMUSA-TPL-Review.pdf title Modified Risk Tobacco Product Application (MRTPA) question first answered 15/11/2021 11:48:11 question first ministerially corrected 16/12/2021 13:06:49 answering member 4909 label Biography information for Lord Kamall previous answer version 31942 answering member printed Lord Kamall attachment 1 file name health-risks-of-scandinavian-snus-consumption-english-summary-pdf.pdf title Health risks of Scandinavian snus consumption 2 file name Modified-Risk-Tobacco-Product-Application-Technical-Project-Lead-Review-Swedish-Match-North-America.pdf title Modified Risk Tobacco Product (MRTP) ApplicationTe answering member 4909 label Biography information for Lord Kamall
tabling member	248 label Biography information for Lord Jones of Cheltenham

1362397

registered interest
date	21/10/2021
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Oral Tobacco: Health Hazards
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government what evidence that they have, if any, which identifies the health risks posed to smokers who switch to snus products.
tabling member printed	Lord Jones of Cheltenham
uin	HL3287
answer	answer is ministerial correction date of answer 15/11/2021 answer text <p>Consumption of any tobacco product is harmful and it is the Government’s policy to support people to quit all forms of tobacco use. Oral tobacco, or snus, is banned in the United Kingdom under the Tobacco and Related Products Regulations 2016.</p><p>There is limited data on the health risks posed to smokers who switch to snus products. Evidence submitted on snus to the United States Food and Drug Administration states that there are still health risks involved with the use of snus. Although snus products contain significantly lower levels of harmful carcinogens than other smokeless tobacco products, the products contain nitrosamines, including NNN and NNK, which have been demonstrated to cause cancer, including cancers of the mouth. A copy of this evidence, <em>Modified Risk Tobacco Product (MRTP) ApplicationTechnical Project Lead (TPL) Review</em>, is attached.</p><p><em>Health risks of Scandinavian snus consumption (English summary)</em> from Norway shows that tobacco products such as oral tobacco contains carcinogenic substances which are associated with a number of adverse health effects. This is regardless of whether the individual is a smoker or not. A copy of this summary is attached.</p> answering member printed Lord Kamall attachment 1 file name health-risks-of-scandinavian-snus-consumption-english-summary-pdf.pdf title Health risks of Scandinavian snus consumption 2 file name SMUSA-TPL-Review.pdf title Modified Risk Tobacco Product Application (MRTPA) question first answered 15/11/2021 11:48:11 question first ministerially corrected 16/12/2021 12:18:50 answering member 4909 label Biography information for Lord Kamall previous answer version 31943 answering member printed Lord Kamall attachment 1 file name health-risks-of-scandinavian-snus-consumption-english-summary-pdf.pdf title Health risks of Scandinavian snus consumption 2 file name Modified-Risk-Tobacco-Product-Application-Technical-Project-Lead-Review-Swedish-Match-North-America.pdf title Modified Risk Tobacco Product (MRTP) ApplicationTe answering member 4909 label Biography information for Lord Kamall
tabling member	248 label Biography information for Lord Jones of Cheltenham

1353663

registered interest
date	07/09/2021
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Health Services: Transgender People
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government what assessment they have made of the processes that NHS trusts use (1) to arrange and specify facilities for transgender patients, and (2) to take into account the needs of other patients who may be sharing facilities with transgender patients.
tabling member printed	Lord Hunt of Kings Heath
uin	HL2490
answer	answer is ministerial correction date of answer 29/09/2021 answer text <p>No assessment has been made of the process used by National Health Service trusts for arranging these facilities nor the provision of single sex wards.</p><p>We expect all NHS trusts to follow all aspects of NHS England and NHS Improvement’s guidance Delivering same-sex accommodation, which sets out the small number of clinical circumstances where mixed-sex accommodation can be justified and also allows, in Annex B, for people to be allocated to wards according to their presentation, such as their preferred dress and pronouns . A copy of the guidance is attached. NHS England and NHS Improvement are currently reviewing this guidance, including whether the Annex is consistent with the provision of single sex wards.</p> answering member printed Lord Kamall question first answered 29/09/2021 15:46:24 question first ministerially corrected 18/10/2021 13:25:12 answering member 4909 label Biography information for Lord Kamall attachment 1 file name Delivering_same_sex_accommodation_sep2019 (1) (1).pdf title Delivering same-sex accommodation previous answer version 24216 answering member printed Lord Kamall answering member 4909 label Biography information for Lord Kamall
tabling member	2024 label Biography information for Lord Hunt of Kings Heath

1353665

registered interest
date	07/09/2021
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Hospital Wards: Gender
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government what assessment they have made as to whether Annex B in NHS England's Delivering same sex accommodation guidance is consistent with the aim to provide of single sex wards by NHS Trusts.
tabling member printed	Lord Hunt of Kings Heath
uin	HL2492
answer	answer is ministerial correction date of answer 29/09/2021 answer text <p>No assessment has been made of the process used by National Health Service trusts for arranging these facilities nor the provision of single sex wards.</p><p>We expect all NHS trusts to follow all aspects of NHS England and NHS Improvement’s guidance Delivering same-sex accommodation, which sets out the small number of clinical circumstances where mixed-sex accommodation can be justified and also allows, in Annex B, for people to be allocated to wards according to their presentation, such as their preferred dress and pronouns . A copy of the guidance is attached. NHS England and NHS Improvement are currently reviewing this guidance, including whether the Annex is consistent with the provision of single sex wards.</p> answering member printed Lord Kamall question first answered 29/09/2021 15:46:25 question first ministerially corrected 18/10/2021 13:25:04 answering member 4909 label Biography information for Lord Kamall attachment 1 file name Delivering_same_sex_accommodation_sep2019 (1) (1).pdf title Delivering same-sex accommodation previous answer version 24218 answering member printed Lord Kamall answering member 4909 label Biography information for Lord Kamall
tabling member	2024 label Biography information for Lord Hunt of Kings Heath

1353666

registered interest
date	07/09/2021
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Hospital Wards: Gender
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government what plans they have, if any, to commission a review of the provision of single sex accommodation by NHS Trusts.
tabling member printed	Lord Hunt of Kings Heath
uin	HL2493
answer	answer is ministerial correction date of answer 29/09/2021 answer text <p>No assessment has been made of the process used by National Health Service trusts for arranging these facilities nor the provision of single sex wards.</p><p>We expect all NHS trusts to follow all aspects of NHS England and NHS Improvement’s guidance Delivering same-sex accommodation, which sets out the small number of clinical circumstances where mixed-sex accommodation can be justified and also allows, in Annex B, for people to be allocated to wards according to their presentation, such as their preferred dress and pronouns . A copy of the guidance is attached. NHS England and NHS Improvement are currently reviewing this guidance, including whether the Annex is consistent with the provision of single sex wards.</p> answering member printed Lord Kamall question first answered 29/09/2021 15:46:25 question first ministerially corrected 18/10/2021 13:24:51 answering member 4909 label Biography information for Lord Kamall attachment 1 file name Delivering_same_sex_accommodation_sep2019 (1) (1).pdf title Delivering same-sex accommodation previous answer version 24219 answering member printed Lord Kamall answering member 4909 label Biography information for Lord Kamall
tabling member	2024 label Biography information for Lord Hunt of Kings Heath